Price: $169.32
· 1 day: +1.46% · 5 days: -0.23% · 1 month: +12.41% · YTD: +38.45%
As of 2026-11-09 21:00 UTC.
52-week range: $116.88 – $176.58 (currently at 88% of the range).
GILD is in an uptrend, momentum firm. $174.48 is the level overhead; $153.51 the first support below.
5 of 6 technical checks lean bullish.
| Trend | Uptrend · above 50-day & 200-day |
|---|---|
| Momentum | RSI 62.68 · bullish · MACD bullish |
| Trend strength | ADX 30.5 · strong trend |
| Location | +10.3% vs 50-day MA |
| 52-week range | -3% from high · +43% from low |
| Volatility | ATR 5.5 · ~3.2%/day |
| Level | Type | Distance |
|---|---|---|
| $174.48 (resistance) | 52w high | 3.05% |
| $200.0 (resistance) | round | 18.12% |
| $153.51 (support) | sma 50 | -9.34% |
| $150.0 (support) | round | -11.41% |
| $142.59 (support) | swing zone | -15.79% |
| RSI (14) | 62.68 | MACD | 5.249 |
|---|---|---|---|
| ADX (14) | 30.5 | ATR (14) | 5.5 |
| 50-day average | $153.51 | 200-day average | $141.13 |
Next earnings: 2026-10-29. GILD earnings date, time and past reactions.
Report of 2026-11-03.
Gilead Sciences (GILD) trades at $169.08 on November 3, 2026, less than 1% below its October 30 closing high of $170.68, after a third-quarter beat and a raised revenue outlook. The weekly uptrend is intact and the stock is outpacing both the S&P 500 and the healthcare sector, so the balance of evidence leans positive, with high conviction (3 of 4 points). The catch is a stretched RSI, thin volume and a breakout whose math does not yet reach 3 to 1.
The quarter that reached the market on October 30 was a clean beat. Adjusted earnings came in at $2.55 a share against a $2.19 consensus, and revenue rose 6.8% to $8.30 billion, according to Benzinga. The quality sits underneath: base business sales of $8.2 billion grew 16%, the strongest in over a decade, with HIV at $6.2 billion and Biktarvy at a record 53% U.S. share, per the call transcript. Full-year revenue guidance moved up to $31.0–$31.3 billion. The one blemish is an adjusted EPS outlook that was cut to a loss, which the coverage ties to acquisitions rather than to the core business.
The market liked it, but not without limit. Shares jumped 4.5% to $172.99 in pre-market trading, Investing.com reported, yet the day ended at $170.68 and the stock has since slipped to $169.08, down 0.73% today while the S&P 500 rose. That is a partial give-back of the opening gain, and it came on volume 54.5% below the 20-day average. With the stock up 16.9% in a month and 37.8% this year, a good deal of the good news was already in the price. The quiet pullback suggests holders are not rushing out.
Over five days the stock gained 6.3% while the S&P 500 lost 2.1% and the healthcare ETF XLV gained 2.8%. The market was a headwind, the sector supplied part of the lift, and GILD beat its sector by 3.5 points, which is the earnings. The sector tailwind is real: Morningstar describes a rotation out of technology into large biopharma, with Gilead named among the leaders.
The argument about GILD is about durability and price, not the quarter. On the positive side, UBS lifted its price target to $195 from $175, citing a revenue beat of about $500 million and a guidance raise of about $900 million, and Morningstar sees a wide moat in the HIV and hepatitis C portfolio. On the negative side, one Seeking Alpha analysis accepts the growth but argues the valuation no longer works, pointing to Medicare pricing that would cut Biktarvy revenue by $1.5 billion a year and take roughly $4.9 billion off equity value. Another Seeking Alpha piece stays neutral, noting that oncology and immunology lag HIV. Two smaller items sit in the background: Reuters reports a tentative FDA nod for Dr Reddy's generic of Gilead's lenacapavir, aimed at 120 low- and middle-income countries, with supply from late 2026. And Baird's note on Lyell mentions an FDA partial clinical hold on Kite's KITE-753. Neither explains this week's move.
On valuation, the 26 analysts rate the stock a buy with a mean target of $172.5, only 2% above the current price, in a range from $131 to $200. The stock is already trading close to what the average analyst says it is worth, so the next leg needs the high targets, like UBS's $195, to be right rather than the average.
The long-term thesis is intact. Price is above its 40-week average, the 50-day average at $151.80 sits above the 200-day at $140.35, and the stock is 43% above its 52-week low of $118.15 and within 1% of the high. It has gained 28.5% in six months. That is a mature advance near its highs, not an early recovery, and the earnings confirmed the fundamentals behind it.
For the next 2–6 weeks the balance of evidence leans positive, and conviction is high at 3 of 4 points. The daily trend runs with the weekly uptrend, and the stock leads the S&P 500 by 13.3% over 50 days and XLV by 4.3%. The strongest case against it is the stretch: RSI is 71.88, volume on the pullback is 54.5% below its 20-day average, and the price is already near the mean analyst target. Such conditions often lead to a pause. They do not tip the balance because the trend structure and relative strength are intact and the drift lower has been orderly. They are, however, why conviction stops short of full.
The structure holds above $153.38, a swing zone, and a break below it would be the first crack. The trend ends below $151.80, the 50-day average, with $150 as a round-number floor beneath it. Further down, the next supports are the $142.59 swing zone and the 200-day average at $140.35. The first two levels sit close together, which makes the area around $152–$153 the line the uptrend depends on.
The breakout level is a daily close above $170.68, the 52-week high, on volume above its 20-day average. Volume is the missing piece today. From there the first target is $175 and the second is $200, against a stop at $152.18, a quarter of an ATR under the $153.38 swing zone. That gives 0.2 to 1 to $175 and 1.6 to 1 to $200. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would need a target far beyond $200 or a stop much closer to the entry, which only happens if price first pulls back toward support.
A weekly close below $151.80, the 50-day average, would change the picture, because it would end the trend that the positive reading rests on. The non-price fact that would most likely do it is evidence that the HIV franchise is losing momentum, such as Biktarvy slipping from its record 53% U.S. share, which would undercut the growth the stock has been rewarded for.
Interactive GILD chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs